IPE, Inc. Completes Phase-OneTesting of Hypothyroid Drug
IPE, Inc. is celebrating the recent success of BCT303, its lead drug candidate to treat hypothyroidism, which completed Phase-One clinical trials at Georgetown University on August 3, 2012, two months ahead of schedule with positive results—none of which could have been possible without the help from some local angel investors.
“This was a real team effort,” says Eric Latham, Chief Executive Officer of IPE. “We brought together good science and business to accomplish this goal.”
BCT303 fixes two problems. Compared to the current branded drug in the market, it is designed to increase safety by delivering more predictive therapeutic levels in patients and improve stability, so it can last longer on the shelf. The hypothyroid market is worth more than $1 billion annually in the United States alone.
Now, BCT303 is ready for Phase-Two clinical trials and IPE is seeking further funding from local angel investors to continue developing this drug.
To learn more, visit www.ipeamerica.com.
